[digital-copyright] Reminder: FTC v Actavis Post Argument Discussion Today at 4:00

["PIJIP" <pijip@xxxxxxxxxxxxxxxx>]

FTC v. Actavis: Post Argument Discussion

Mar 25, 2013 | 4:00-5:30 | Room 602
American University Washington College of Law
4801 Massachusetts Ave., NW, Washington DC (Directions)

Webcast will be availabe at
http://www.pijip-impact.org/events/ftc-v-watson/

In PIJIPbs ongoing Supreme Court series, counsel for parties and
amici will discuss intellectual property cases on the afternoon
of oral argument, addressing the reaction of the Court at oral
argument.  In this case the Supreme Court examines whether
reverse-payment agreements are per se lawful unless the
underlying patent litigation was a sham or the patent was
obtained by fraud (as the court below held), or instead are
presumptively anticompetitive and unlawful (as the Third Circuit
has held).  Reverse payment agreements are a type of settlement
agreement where brand-name drug manufacturers pay potential
generic competitors to agree not to sell competing generic drugs for a period
of years.

- Michael Carroll b Washington College of Law, Moderator
- Julia York b Skadden, Arps, Slate, Meagher & Flom LLP, counsel for
Respondent, Actavis, Inc.
- Rohit Singlab Munger, Tolles & Olson LLP, counsel for Respondent, Solvay
Pharmaceuticals, Inc.
- Ryan Christian b White & Case LLP, counsel for Respondent, Par
Pharmaceutical Companies, Inc.
- Julia York b Skadden, Arps, Slate, Meagher & Flom LLP, counsel for
Respondent, Actavis, Inc.
- Krista Cox b Knowledge Ecology International, counsel for amicus Knowledge
Ecology International, supporting Petitioner
- Scott Hemphill b Columbia Law School


For more information, please contact pijip@xxxxxxxxxxxxxxxx

--
4801 Massachusetts Ave., NW
Washington, DC 20016
United States

http://emarketing.wcl.american.edu/private/Mp2o/6kD/VEutS1q/unsubscribe/18276
453